Generics & lower flu vac sales hit Sanofi-Aventis (SNY, SAN.PA)

Generics & lower flu vaccine sales hit Sanofi-Aventis (SNY, SAN.PA)

Sanofi-Aventis provided guidance that earnings per share could drop 5-10 % this year.
http://sanofi-aventis.mediaroom.com/index.php?s=43&item=311

“Despite the absence of A/H1N1 vaccines sales and the impact of generic competition, double digit sales increase(6) of growth platforms and cost control should lead to 2011 business EPS(1) 5% to 10% lower at CER than 2010 business EPS(7), barring major unforeseen adverse events. This guidance does not assume a return of generics of Eloxatin® in the U.S. and does not include any benefit from a possible acquisition of Genzyme.”